MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.xkme.2026.101497

Медицинская библиотека · Kidney medicine · 2026

Cost-Effectiveness of Dapagliflozin in the Treatment of Patients With Chronic Kidney Disease in Denmark.

Kjær Thea Tanderup, Lindhardt Morten, Riis Anders Hammerich, Birn Henrik, Ehlers Lars Holger

СтатьяПеревод пока не подготовлен

Аннотация

RATIONALE &

OBJECTIVE

Chronic kidney disease (CKD) is a growing burden worldwide and in Denmark, with substantial clinical and economic consequences. Although national guidelines recommend sodium/glucose transporter 2 inhibitors (SGLT2i) for patients with CKD, type 2 diabetes (T2D) or heart failure (HF), underdiagnosis limits the use of SGLT2i. This study aims to inform decision makers in health care about the cost-effectiveness of current guidelines for CKD in Denmark focusing on SGLT2i dapagliflozin added to standard of care (SoC) versus SoC alone in patients with CKD.

STUDY

DESIGN

Cost-effectiveness analysis based on a Markov model with a lifetime horizon.

SETTING &

PARTICIPANTS

Danish health care payer perspective including a broad population with CKD and subgroups stratified by urinary albumin-creatine ratio (UACR), T2D status, and HF history.

EXPOSURES: Dapagliflozin plus SoC versus SoC alone.

OUTCOMES: Quality-adjusted life years (QALYs), life-years, total costs, and incremental cost-effectiveness ratios (ICERs).

ANALYTICAL APPROACH: A published Markov model was populated using data from the DAPA-CKD and DECLARE-TIMI 58 trials. Analyses were conducted for the overall population and stratified subgroups. Results were evaluated against an assumed willingness-to-pay (WTP) threshold of €24,158 per QALY.

RESULTS

Dapagliflozin treatment resulted in health benefits (QALYs) and life-years versus SoC irrespective of T2D/HF status or UACR levels. Dapagliflozin was cost-effective for the total population with an ICER of €7,499/QALY and dominant for subgroups with high UACR (≥200 mg/g) regardless of T2D/HF status. ICERs were below WTP threshold for all subgroups. However, for patients with CKD and low UACR (<200 mg/g) without T2D/HF, time to cost-effectiveness was long, and estimates were uncertain.

LIMITATIONS: Results are limited by generalizability, long-term uncertainty, simulated subgroup data, cost uncertainty, and lack of a Danish WTP threshold.

CONCLUSIONS

This study indicates that dapagliflozin added to SoC is cost-effective across CKD subgroups as recommended in the current Danish guideline recommendations.

Для цитирования: Kjær Thea Tanderup, Lindhardt Morten, Riis Anders Hammerich, Birn Henrik, Ehlers Lars Holger. Cost-Effectiveness of Dapagliflozin in the Treatment of Patients With Chronic Kidney Disease in Denmark.. Kidney medicine. 2026. DOI: 10.1016/j.xkme.2026.101497.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.